Phase I Study of TAS-102 Administered to Japanese Patients with Advanced Solid Tumors
Phase 1
- Conditions
- Patients with solid tumors
- Registration Number
- JPRN-jRCT2080221506
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Signed, written informed consent.
- Histologically or cytologically confirmed solid tumor.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
Exclusion Criteria
- Patient who has serious concomitant disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety<br>CTCAE (ver.3.0)
- Secondary Outcome Measures
Name Time Method Pharmacokinetics,Efficacy<br>RECIST (ver.1.0)